涉及人类肿瘤细胞系的体外细胞毒性评估显示,与多柔比星相比,AVA6000的细胞毒性低80倍到4,000倍。在对FAP水平较高的肿瘤进行的几项体内疗效研究中,AVA6000以剂量依赖的方式显著减少了肿瘤体积,提高了存活率。在骨肉瘤的PDX模型中,AVA6000能明显缩小肿瘤体积,而多柔比星则无明显效果。 AVA6000临床试验进展 一项1a期...
“我们很高兴AVA6000获得FDA给予的孤儿药认定,这反映了preCISION平台可以为癌症患者带来潜在收益,以及该药临床前研究数据的高质量,”Avacta Group首席执行官Alastair Smith博士在新闻稿中表示。 值得注意的是,如果AVA6000之后获批用于治疗软组织肉瘤,此项孤...
AVA6000是一种基于pre-CISION专利技术的治疗产品,含有一种对成纤维细胞活化蛋白α(FAP)裂解敏感的底物。2具体而言,该药剂由一个与二肽共价键合的多柔比星分子组成,该二肽被设计为容易被FAP水解,但对密切相关和更广泛的哺乳动物肽酶的水解有抵抗力。该制剂可以直接将多柔比星输送到肿瘤微环境中,同时使病人面临较...
傲华AVA6000分布式存储系统是由深圳傲华科技有限公司著作的软件著作,该软件著作登记号为:2015SR158929,属于分类,想要查询更多关于傲华AVA6000分布式存储系统著作的著作权信息就到天眼查官网!
The results demonstrate that AVA6000 is well-tolerated across the every 2 weeks and every 3 weeks dosing schedules with early evidence of efficacy supported by ongoing and durable RECIST responses in patients with FAPhighdisease. AVA6000 is the first peptide drug conjugate (PDC) in the Avacta ...
AVA6000 is a therapeutic product based on proprietary pre|CISION technology which incorporates a substrate that is sensitive to cleavage by FAP. The pre|CISION substrate can be utilized in a drug conjugate linker or to generate chemotherapy prodrugs that are only activated in the tumor ...
AVA6000 is the first peptide drug conjugate in Avacta’s pipeline and consists of doxorubicin conjugated with Avacta’s proprietary pre|CISION®peptide, that is specifically cleaved by fibroblast activat...
AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s preCISION platform to improve its safety and therapeutic index. Anthracyclines such as doxorubicin, a generic chemotherapy for which the market is expected to grow to $1.38 billion by 2024, are widely used as part of...
Avacta. AVA6000 offers an opportunity to improve upon the current doxorubicin treatment paradigm for patients, either as a monotherapy or in combination. We look forward to the results from our AVA6000 first-in-human clinical trial as we strive to improve therapeutic index of doxorubicin for ...
AVACTA GROUP PLC ORD 10P (AVCT) 公告正文 重要股东股权质押数据全览 个股公告查询: AVA6000 Abstract Release by AACR 下载附件 公告日期:2024年04月08日[点击查看原文] 郑重声明:本网不保证其真实性和客观性,一切有关该股的有效信息,以交易所的公告为准,敬请投资者注意风险。数据来源:东方财富Choice...